Humacyte announced the addition of John Bamforth and Dr. Keith Anthony Jones to the Company’s Board of Directors. John P. Bamforth, PhD has served as Executive Director of Eshelman Innovation, a translational innovation institute at the University of North Carolina-Chapel Hill, since 2019. Keith Anthony Jones, M.D., has served as the Chief Physician Executive of the University of Alabama at Birmingham Health System since 2017.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte price target raised to $11 from $8 at BTIG
- Pluristyx announces license agreement with Humacyte for iPSCs
- Humacyte RMAT designation for ATEV positive for stock, says Benchmark
- Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
- Humacyte granted RMAT designation for Acellular Tissue Engineered Vessel